news
TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in ErlangenTAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen
biomarker, circulating miRNAs, Conference, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA
TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen
From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in [...]
TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague
From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a [...]
TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026
biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA
TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026
Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to [...]
Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing
New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose [...]
Why Spike-ins Are the Key to Reproducible Small RNA-seq Data
Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly [...]
A New Milestone in EV-Based Therapies Research
A major hurdle in EV-based therapies is the "yield gap" — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs. In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA [...]
New publication in Biomaterials
Huge congrats to Cansu Gorgun and the teams at Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin on their new publication in Biomaterials! This study is a fascinating look at how we can "train" macrophages to do two things at once. By reprogramming their metabolism, the team produced hybrid M1/M2 extracellular vesicles — a "dual-action" package that combines pro-inflammatory and [...]
TAmiRNA @ RNA Leaders Europe Conference
Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, [...]
Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes
TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type [...]
New white paper with RoosterBio on omics-tools for EV characterization
In this white paper, TAmiRNA and RoosterBio present a comprehensive small RNA-sequencing–based characterization of mesenchymal stem cell (MSC)–derived exosomes produced using RoosterBio’s standardized, xeno-free manufacturing platform. The study was designed to assess both the analytical robustness of TAmiRNA’s miND® small RNA-sequencing workflow and the biological relevance of microRNA cargo profiling as an advanced “omics-based” characterization strategy for therapeutic extracellular vesicles (EVs). Using technical [...]